Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Pharmacy Profile · Updated 2026-06-19

Hallandale Pharmacy

Hallandale Pharmacy operates both 503A patient-specific compounding and 503B FDA-registered outsourcing facility services from Hallandale Beach, Florida. PCAB-accredited with FDA registration on the 503B side.

503A & 503B CompoundingHallandale Beach, FLFounded 2010
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19

About Hallandale Pharmacy

Hallandale Pharmacy operates both 503A patient-specific compounding and 503B FDA-registered outsourcing facility services from Hallandale Beach, Florida. PCAB-accredited with FDA registration on the 503B side.

Hallandale Pharmacy at a glance

Type
503A & 503B Compounding
Headquarters
Hallandale Beach, FL
Founded
2010
Licensure
Multi-state (verify per shipment)

Accreditations & quality

PCABFDA-registered 503B Outsourcing FacilityUSP <797>USP <800>

What Hallandale Pharmacy does

Sterile injectable compounding including semaglutide and tirzepatide, dispensed via both 503A and 503B pathways. Office-stock fulfillment available through the 503B facility.

Transparency

FDA 503B registration verifiable through FDA's public outsourcing facility database. Per-batch CoAs available.

Patient-reported quality signals

Through US Telehealth Review's review of NexLife users, patients reported high quality medication delivered from reputable pharmacies. Specific signals patients valued and verified:

Used by which providers?

Hallandale Pharmacy is part of NexLife's pharmacy network for compounded semaglutide.

Verifying Hallandale Pharmacy

Other pharmacies

All 6 pharmacy partners →

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing